Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2003
03/04/2003US6528532 Benzenesulfonamide group
03/04/2003US6528530 Side effect reduction; mainly the D-threo stereoisomer of a phenidate
03/04/2003US6528528 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
03/04/2003US6528527 N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide or the pyridyl-N-oxide thereof
03/04/2003US6528526 Inhibition of cell proliferation and/or cell matrix production and/or cell movement (chemotaxis) and/or T cell activation and proliferation
03/04/2003US6528525 Amidocarboxylic acid derivatives
03/04/2003US6528524 Treating the multiple drug resistance, arrhythmia, spasms and malaria; reacting hydrochloric acid with cinchonine or to cinchonine monohydrochloride in form cinchonine dihydrochloride; high purity
03/04/2003US6528523 N-acyl- or N-sulfonylpiperidine substituted tricyclic benzocycloheptenepyridine derivatives
03/04/2003US6528522 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
03/04/2003US6528521 Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
03/04/2003US6528520 Method of treating the syndrome of coronary heart disease risk factors in humans
03/04/2003US6528519 Use of tetrandrine and its derivatives to treat malaria
03/04/2003US6528518 Treatment of depression with kappa receptor antagonists
03/04/2003US6528516 Methods for reducing intraocular pressure using A3 adenosine receptor antagonists
03/04/2003US6528515 Beta-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (beta -FTC) and penciclovir
03/04/2003US6528514 Pyrimidin-4-one-5-amino-3-alkylcarboxamidomethyl compounds
03/04/2003US6528513 Viricides; especially cytomegalo virus
03/04/2003US6528512 Cytokine specific binding protein;
03/04/2003US6528511 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
03/04/2003US6528510 HIV protease inhibitors
03/04/2003US6528509 Pyrazole compositions useful as inhibitors of ERK
03/04/2003US6528508 A bicyclic nitrogen containing heteroaromatic compound useful for inhibiting protein kinase p38 which involved in cell proliferation, cell death and response to extracellular stimuli
03/04/2003US6528507 Arginine salt of 3-(4-(2-(phenoxazin-10-yl)ethoxy) phenyl)-2-ethoxypropanoic acid
03/04/2003US6528506 Viability of organs transplants
03/04/2003US6528502 Composition and method for improved carbohydrate management in mammals
03/04/2003US6528501 Control of fertility
03/04/2003US6528498 Selection and/or enhancement of resident microorganisms in the gastrointestinal tract
03/04/2003US6528497 Anticoagulant and antithrombotic like heparin; hexadeca saccharides of three distinct sequences: a sulphated penta saccharide sequence DEFGH, a non-sulphated heptasaccharide sequence Z(MN)3 and a sulphated tetrasaccharide sequence VWXY.
03/04/2003US6528496 Vitamin B12 and folic acid for elevated serum metabolite levels of homocysteine (HC), cystathionine (CT), methylmalonic acid (MMA), or 2- methylcitric acid (2-MCA)
03/04/2003US6528495 Aryl phosphate derivatives of d4T having anti-HIV activity
03/04/2003US6528494 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
03/04/2003US6528493 Modulating activity of endogenous protein
03/04/2003US6528490 Plant extracts; free radical scavengers; antiinflammatory agents
03/04/2003US6528312 Nuclease inhibitor (G-Actin) or interleukin-10 (IL-10) use improving cell transfection; mixtures; polynucleotides; use gene therapy, vaccines
03/04/2003US6528306 Engraftable human neural stem cells
03/04/2003US6528304 Eukaryotic cells expressing at their surface at least an HLA-G isoform and their applications
03/04/2003US6528271 Drug screening
03/04/2003US6528096 Carrier mixed with additives having lubricant properties for preparing powdery pharmaceutical compositions for inhalation
03/04/2003US6528094 Storage stable, shaped particles of allotropic organic compounds. The particles of the present invention can be shaped according to the desired application. Preferred shapes of such particles are microspheres,
03/04/2003US6528091 A method of treating epilepsy comprising administering once daily to a patient in need of such treatment a controlled release tablet dosage form comprising a daily therapeutic dose of divalproex sodium from about 50 to 55 weight percent in a
03/04/2003US6528090 Controlled release formulation of divalproex sodium
03/04/2003US6528089 Solid dosage forms are obtained by mixing at least one polymeric binder, at least one active ingredient, and additives to form a plastic mixture, and shaping, using as polymeric binder a copolymer of an N-vinyllactam
03/04/2003US6528087 Kits for forming protein-linked lipidic microparticles
03/04/2003US6528086 Methods and apparatus for drug delivery involving phase changing formulations
03/04/2003US6528082 Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
03/04/2003US6528077 Cataplasms containing vitamin C or its derivative
03/04/2003US6528076 Acetone, a salicylate-based compound and an emollient.
03/04/2003US6528072 A topical composition applicable to skin for clearing the complexion, including magnesium hydroxide, witch hazel, an analgesic, and alcohol.
03/04/2003US6528053 Reducing buildup in the blood and normalizing cholesterol and blood pressure, in a mammal. The compositions comprise Morinda citrifolia extract, red wine extract, prune extract, blueberry extract, pomegranate extract, apple extract, and an
03/04/2003US6528040 EMU oil-based formulations for use as an analgesic, anesthetic and antipruritic
03/04/2003US6528037 Method for determining whether a compound is an insulin receptor kinase activator
03/04/2003CA2401452A1 Combination of antioxidant substances for the treatment of alzheimer's disease
03/04/2003CA2400565A1 Biomodulated multiparticulate formulations
03/04/2003CA2218913C Substituted oximes, hydrazones and olefins as neurokinin antagonists
03/04/2003CA1341424C Diketohexanoic acids and 2- and 3-diloweralkyl derivatives thereof
03/04/2003CA1341423C Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
03/03/2003WO2002020496A1 2-guanidino-4-aryl-quinazoline
03/03/2003WO2002020491A1 Arylpiperazine derivatives and their use as psychotropic agents
03/03/2003WO2002019971A1 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds
03/03/2003CA2421222A1 2-guanidino-4-aryl-quinazoline
03/03/2003CA2421219A1 Arylpiperazine derivatives and their use as psychopharmaceuticals
02/2003
02/28/2003WO2002020009A1 Medicinal compositions
02/28/2003WO2002017913A1 Medicinal compositions for preventing or treating heart failure
02/28/2003CA2420951A1 Medicinal compositions
02/28/2003CA2420844A1 Medicinal compositions for preventing or treating heart failure
02/28/2003CA2399567A1 Crystalline material
02/28/2003CA2356099A1 Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degeneration
02/27/2003WO2003016917A2 Sodium channel regulators and modulators
02/27/2003WO2003016915A1 Tumor specific oligosaccharide sequences and use thereof
02/27/2003WO2003016867A2 Method and quantification assay for determining c-kit/scf/pakt status
02/27/2003WO2003016781A2 Surface plasmon enhanced illumination system
02/27/2003WO2003016567A2 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides
02/27/2003WO2003016563A2 Novel molecular target for neurotoxicity
02/27/2003WO2003016544A1 Process for producing 1,4-dihydroxy-2-naphthoic acid
02/27/2003WO2003016532A1 Human protooncogene kg-20 and protein encoded therein
02/27/2003WO2003016528A2 Oligonucleotide compositions and their use to induce apoptosis
02/27/2003WO2003016499A2 Combinatorial methods for inducing cancer cell death
02/27/2003WO2003016493A2 Transporters and ion channels
02/27/2003WO2003016469A2 Chemo-enzymatic synthesis of sialylated oligosaccharides
02/27/2003WO2003016464A2 Cancer specific oligosaccharide sequences and use thereof
02/27/2003WO2003016334A1 Methods for purification of an activated peg solution and for the synthesis of a modified hemoglobin solution
02/27/2003WO2003016333A2 Virus coat protein/receptor chimeras and methods of use
02/27/2003WO2003016326A1 Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient
02/27/2003WO2003016325A1 Association compound of trehalose or maltitol with metal ion compound
02/27/2003WO2003016318A1 Tumour inhibiting lanthane compounds
02/27/2003WO2003016317A1 Processes for preparing calcium salt forms of statins
02/27/2003WO2003016316A1 Diazacycloalkanes as oxytocin agonists
02/27/2003WO2003016315A1 Sodium salt of an hiv integrase inhibitor
02/27/2003WO2003016314A1 1-alkyl 0r 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
02/27/2003WO2003016313A1 New compounds for treating impotence
02/27/2003WO2003016310A1 Alkyl-substituted imidazopyridines for the treatment of gastrointestinal disorders
02/27/2003WO2003016306A1 Hiv inhibiting pyrimidines derivatives
02/27/2003WO2003016305A1 Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
02/27/2003WO2003016302A1 Diamine derivatives
02/27/2003WO2003016289A1 Triazine derivatives and their use as sunscreens
02/27/2003WO2003016288A1 Fxr nr1h4 nuclear receptor binding compounds
02/27/2003WO2003016285A1 Method of preparing 4-(imidazole-1-il)benzenesulphonamide derivatives
02/27/2003WO2003016284A1 Substituted anthranilamides for controlling invertebrate pests
02/27/2003WO2003016283A1 Substituted dihydro 3-halo-1h-pyrazole-5-carboxylates their preparation and use
02/27/2003WO2003016282A2 Substituted 1h-dihydropyrazoles, their preparation and use
1 ... 5548 5549 5550 5551 5552 5553 5554 5555 5556 5557 5558 5559 5560 5561 5562 5563 5564 5565 5566 5567 5568 ... 7860